profit from every $100 of sales.
$0$100
Arcus Biosciences
$17.43-1.91% today
-11.9% in 1 year
1-year low $17.431-year high $31.57
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Arcus Biosciences sold, what it kept, and what it did with the cash.
Sales went from $112 million in 2022 to $247 million in 2025, with -$353 million of profit last year.
SalesProfit
Arcus Biosciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Arcus Biosciences | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Arcus Biosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 112 | 117 | 258 | 247 | |
| – | – | – | – | |
| -280 | -340 | -310 | -386 | |
| -258 | -291 | -268 | -335 | |
| -267 | -307 | -283 | -353 | |
| -3.71 | -4.15 | -3.14 | -3.29 | |
| – | – | – | – | |
| -250.0% | -290.6% | -120.2% | -156.3% | |
| -238.4% | -262.4% | -109.7% | -142.9% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,345 | 1,095 | 1,150 | 1,139 |
| Cash | 206 | 127 | 150 | 222 |
| Total debt | 3 | 11 | 60 | 112 |
| Total liabilities | 688 | 633 | 665 | 508 |
| 657 | 462 | 485 | 631 | |
| 72 | 74 | 90 | 107 | |
| -31.6% | -49.9% | -40.3% | -36.7% | |
| -40.6% | -66.5% | -58.4% | -55.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 438 | -306 | -170 | -482 | |
| 6 | 24 | 6 | 2 | |
| 432 | -330 | -176 | -484 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 65 | 73 | 76 | 60 |
Valuation
- –
- –
- –
- 6.0×
- 10.2×
- –
- –
- -19.3%
- -14.1%
- 0.0%
Profitability
- 97.0%
- -156.3%
- -142.9%
- -143.6%
- -50.5%
- -38.8%
- -69.0%
- -37.0%
- -50.5%
- 221.6%
Growth
- +30.2%
- –
- −175.0%
- –
- +11.6%
Financial health
- -0.3×
- 0.19
- 10.0%
- -18.1×
- 4.04
- 4.04
- 0.24
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 6%of 952
Bottom 2%of 884
Top 18%of 886
Bottom 4%of 987
What analysts expect
- Average price target
- $30.00
- Range
- $20.00 – $47.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -1.02 | -0.92 | −10.9% |
| Feb 25, 2026 | -0.89 | -1.11 | +19.8% |
| Oct 28, 2025 | -1.27 | -1.33 | +4.5% |
| Aug 6, 2025 | -0.08 | -1.14 | +93.4% |
| May 6, 2025 | -1.14 | -1.02 | −11.8% |
| Feb 25, 2025 | -1.03 | -1.17 | +12.0% |
| Nov 6, 2024 | -1.00 | -1.07 | +6.5% |
| Aug 8, 2024 | -1.02 | -1.02 | +0.0% |
News
Arcus Biosciences slides 20% on stock offering, kidney-cancer dataSeeking Alpha · Oct 21, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
39No pass
Benjamin Graham
41No pass
Philip Fisher
53No pass
Peter Lynch
72Pass
Joel Greenblatt
2No pass
Charlie Munger
41No pass
Terry Smith
51No pass
Questions about Arcus Biosciences
Is Arcus Biosciences a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Arcus Biosciences AI analysis
What does Arcus Biosciences do?
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. It is in Biotechnology, based in Hayward, CA, United States, with 601 employees.
Does Arcus Biosciences pay a dividend?
No. Arcus Biosciences does not pay a dividend at the moment.
Is Arcus Biosciences stock halal?
No. Arcus Biosciences does not pass our halal screen: its cash and confirmed interest-bearing investments are 39% of its market value, at or above the 33% limit. How we check
How has Arcus Biosciences stock done over the past year?
Down 11.9% over the past twelve months, to $17.43. It traded between $17.43 and $31.57 and is 44.8% below its high.
Who are Arcus Biosciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Arcus Biosciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.